ASTRAZENECA UK LIMITED

Their core work

AstraZeneca is a global biopharmaceutical company headquartered in Cambridge, UK, focused on the discovery, development, and commercialization of prescription medicines across oncology, cardiovascular, renal, metabolic, and respiratory diseases. In H2020, they primarily serve as an industry host within Marie Skłodowska-Curie training networks, providing early-stage researchers access to pharmaceutical R&D environments, proprietary compound libraries, and drug development pipelines. Their participation bridges academic research with industrial drug discovery, contributing disease models, clinical data, and translational expertise to large multi-partner consortia.

What they specialise in

How they've shifted over time

Early H2020 participation (2015–2018) centered on computational and data-driven approaches — big data analytics for healthcare, machine learning methods, molecular dynamics simulations, and mathematical modelling of biological systems. From 2019 onward, their focus shifted decisively toward translational biology and advanced experimental platforms: organ-on-chip systems, cancer organoid screening, bone pain models, obesity stratification, and intracellular transport mechanisms. This trajectory mirrors the broader pharma industry's move from in silico discovery toward complex in vitro disease models that better predict clinical outcomes.

AstraZeneca is investing in organ-on-chip and organoid technologies as next-generation drug screening platforms, making them a strong partner for groups developing microphysiological systems or alternative testing methods.

How they like to work

AstraZeneca never coordinates H2020 projects — they participate exclusively as a partner or third party, consistent with large pharma's typical role of providing industrial context, compounds, and training placements rather than managing academic consortia. With 210 unique partners across 26 countries, they operate as a hub connecting to a very wide network, primarily through MSCA training networks (6 of 11 projects). This means they are experienced at hosting early-stage researchers and integrating into large, multi-institutional collaborations without seeking administrative control.

Exceptionally broad network of 210 unique consortium partners spanning 26 countries, built primarily through large MSCA training networks. Their reach covers most of Europe with no narrow geographic concentration, reflecting their status as a global pharma partner of choice for academic consortia.

What sets them apart

AstraZeneca brings what most academic consortia cannot access on their own: industrial-scale drug development infrastructure, proprietary compound libraries, and real-world clinical datasets. Unlike smaller pharma participants, they offer training placements within an active R&D pipeline spanning oncology, cardiovascular, and metabolic diseases. For consortium builders, their participation signals credibility and translational relevance — they are selective about which projects they join, and their involvement validates the commercial potential of the science.

Highlights from their portfolio

• IMMUcan
  Large-scale immunoprofiling initiative across five major cancer types using advanced techniques (CyTOF, RNAseq, microbiome analysis), running until 2026 — their longest-running H2020 commitment.
• PRECODE
  Pancreatic cancer organoid network combining high-throughput drug screening with next-generation sequencing and metabolomics — directly aligned with AstraZeneca's oncology pipeline.
• EUROoC
  European training network for organ-on-chip technology, positioning AstraZeneca at the frontier of alternatives to animal testing for drug development.